

FEM Women's Wellness Andrea Thompson, APRN, PMHNP 5448 Reno Corporate Drive Reno, Nevada 89511 775-993-9292

September 11, 2024

Nevada Medicaid review board:

I would like to request that Rexulti (brexpiprazole) remain on the Nevada Medicaid formulary with no restrictions for the upcoming 2025 calendar year.

In my clinical experience treating patients diagnosed with Major Depression Disorder, I have found Rexulti to significantly reduced pressive symptoms, particularly those with suicidal ideation, when used in combination with the patient's current antidepressant.

It is imperative that providers and clinicians continue to have access to medications that can help our most vulnerable patients to build on the important progress they have already made in the treatment of their mental health. Please continue to support patients with this requested need.

Regards,

Andrea Thompson, APRN, FNP-C, PMHNP-BC, PMH-C